Table 8. Validation of proposed signatures on data collected at 12 month follow-up.

Signature	Sens	Spec	MCC
Control v MCI Progressor – Single Analyte Signature
Signature with APOE
a Full set of samples	79.3	56.2	0.36
b Size-matched groups	65.8	70.8	0.37
Signature without APOE
a Full set of samples	79.1	37.0	0.18
b Size-matched groups	57.4	49.6	0.07
Control v MCI Progressor – Pair-Wise Differences Signature
Signature with APOE
a Full set of samples	71.7	45.4	0.17
b Size-matched groups	58.2	59.8	0.18
Signature without APOE
a Full set of samples	81.2	42.8	0.27
b Size-matched groups	66.2	59.4	0.26
Control v AD – Single Analyte Signature
Signature with APOE
c Full set of samples	81.9	68.6	0.51
d Size-matched groups	72.8	81.4	0.55
Signature without APOE
c Full set of samples	79.4	55.6	0.37
d Size-matched groups	61.6	69.6	0.32

^aThe full set of samples contained data on 50 Controls and 92 MCI Progressors.

^bThe size-matched groups contained data on 50 Controls and 50 MCI Progressors.

^cThe full set of samples contained data on 50 Controls and 97 AD patients.

^dThe size-matched groups contained data on 50 Controls and 50 AD patients.